Map your greying profile.

The findings that opened the window

The compound-level evidence

1. 01

   Redox compatibility.

   Each antioxidant must regenerate its partners rather than oxidising them. Luteolin and ascorbate were selected because the catechol B-ring of luteolin forms reversible semiquinone intermediates that ascorbate is competent to reduce — a working redox cycle, not two separate antioxidants.

2. 02

   Cofactor dependency.

   Melanin biosynthesis requires Copper for tyrosinase and the one-carbon lane for methylation; neither is useful alone. The formulation resolves the cofactor graph so every substrate has its catalyst and every catalyst has its lane.

3. 03

   Methylation-lane fit.

   Cobalamin, folate, pyridoxine, and choline run the one-carbon metabolism lane melanocytes depend on. The doses are ratio-fitted to each other, not only to their own published targets, to avoid the homocysteine imbalance a single nutrient at a clinical dose can produce.

4. 04

   Absorption and form.

   Every compound is carried in the chemical form its clinical evidence used — luteolin as its aglycone, ashwagandha as a standardised withanolide extract, copper as the gluconate salt. No methylated or proprietary form smuggles a different pharmacology in under a name the evidence never tested.

5. 05

   Two-capsule discipline.

   The above four constraints were resolved against a fifth: everything has to fit inside two capsules a day. Most formulations solve the first four by asking for four, six, eight capsules. Anti Grey 1.0 solves them at two.

Composition

Clinical trichology · nutrition science · pharmacy manufacturing

Geography

UK · US

Advisory review

Formulation stage

Manufacture

By pharmacists

Origin

Authored in Kensington, London

Education Faculty